Janssen-Cilag International NV clinical trials

A subsidiary of Johnson & Johnson

The registry lists 67 studies whose lead sponsor is Janssen-Cilag International NV. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 67. List all 67 → · All Johnson & Johnson studies →

• A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque PsoriasisActive, not recruitingNCT03218488

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type PsoriasisCompletedNCT03818035Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive DisorderCompletedNCT04338321Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant DepressionWithdrawnNCT03852160Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739CompletedNCT03088644Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthlyCompletedNCT03809325

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive DisorderCompletedNCT02476058Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female ParticipantsCompletedNCT03151486Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With SchizophreniaCompletedNCT00460512Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274CompletedNCT02852395Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl EstradiolCompletedNCT03547024Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare SettingsCompletedNCT04940039Phase 4

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult ParticipantsCompletedNCT03249402Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739CompletedNCT03437590Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy ParticipantsCompletedNCT02812251Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study of Orally Administered Pimodivir in Adult Participants With Hepatic ImpairmentCompletedNCT03816631Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During RamadanCompletedNCT02737657

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy ParticipantsCompletedNCT02475148Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study of Orally Administered Pimodivir in Adult Participants With Renal ImpairmentTerminatedNCT03947814Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male ParticipantsCompletedNCT02515955Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line TreatmentCompletedNCT01709084Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Determine the Epidemiology and Evaluate the Burden of Disease in Respiratory Syncytial Virus/Human Metapneumovirus and Influenza A Infected Hospitalized Participants (Adults and Children)CompletedNCT03574532

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy AdultsCompletedNCT03768609Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute GastroenteritisTerminatedNCT02699385Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy AdultsCompletedNCT03105986Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy AdultsCompletedNCT02860806Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current TreatmentCompletedNCT01448707Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male ParticipantsCompletedNCT01650597Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult ParticipantsCompletedNCT03023852Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected ParticipantsCompletedNCT02268864Phase 2

  Sponsor listed in the registry: Janssen-Cilag International NV

• Study to Evaluate Optimized Retreatment and Prolonged Therapy With BortezomibCompletedNCT01910987Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy ParticipantsCompletedNCT02230878Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02278419Phase 2

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV InfectionCompletedNCT01846832Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• Telaprevir Open-Label Study in Co-Infected PatientsCompletedNCT01500616Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver TransplantationCompletedNCT01571583Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• Velcade Consolidation Bone StudyCompletedNCT01286077Phase 2

  Sponsor listed in the registry: Janssen-Cilag International NV

• Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.CompletedNCT01601379

  Sponsor listed in the registry: Janssen-Cilag International NV

• An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)CompletedNCT01513941Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy ParticipantsCompletedNCT02578472Phase 1

  Sponsor listed in the registry: Janssen-Cilag International NV

• An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic SyndromesCompletedNCT01381809Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital SettingCompletedNCT01926912

  Sponsor listed in the registry: Janssen-Cilag International NV

• Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C SubjectsNo longer availableNCT01508286

  Sponsor listed in the registry: Janssen-Cilag International NV

• Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral AntipsychoticsCompletedNCT01081769Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis CCompletedNCT01498068Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VDCompletedNCT00908232Phase 2

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With PlaceboCompletedNCT01813890Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV

• A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to MethotrexateCompletedNCT01059773Phase 4

  Sponsor listed in the registry: Janssen-Cilag International NV

• An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple MyelomaCompletedNCT00431769Phase 2

  Sponsor listed in the registry: Janssen-Cilag International NV

• A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With SchizophreniaCompletedNCT00645099Phase 3

  Sponsor listed in the registry: Janssen-Cilag International NV